Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Alexion Pharmaceuticals, Inc.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma, Inc.

Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates in China, US, and the rest of the world.

Xynomic Pharmaceuticals Holdings, Inc.

rAAVen Therapeutics specializes in developing next-generation gene therapy vectors, focusing on generating novel AAV capsids for a variety of disorders using cutting-edge methodologies in cloning, virus production, and sequencing.

rAAVen Therapeutics

Alexion develops innovative medicines and research aimed at helping people living with rare diseases.

Metric
Company Name	Alexion Pharmaceuticals, Inc.	Sutro Biopharma, Inc.	Xynomic Pharmaceuticals Holdings, Inc.	rAAVen Therapeutics
Symbol	0QZM	STRO
MSH ID	COM:ALEXION	COM:SUTROBIO	COM:XYNOMICPHARMA	SE:RAAVEN
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Pharmaceuticals	Biotechnology	Pharmaceuticals	Biotechnology
Country	US	US	US	SE
Stage		Post-IPO Equity	Series B
Employee Count	3.84K	300
Website	alexion.com	sutrobio.com	xynomicpharma.com	raaven.se
LinkedIn
Founders

Metric
Market Cap	294.46M
Enterprise Value
Monthly Web Traffic	9.82K	1.52K
Web Traffic Growth	0.04	4.19
Valuation
Raised Capital	75M

Metric
Revenue		153.73M
Revenue (LTM)
Revenue (NTM)
Gross Profit		146.91M
EBITDA		-82.46M
Operating Income		-89.28M
Net Income		-106.79M
EPS		-1.78
Diluted EPS		-1.78
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.96
Operating Profit Margin		-0.58
EBITDA Margin		-0.54
Net Profit Margin		-0.69
Return on Equity		-0.71
Return on Assets		-0.23
Return on Capital Employed		-0.24

0QZM

COM:ALEXION

Alexion

Last Close

179.05

01/01 00:00

Volume Today

253

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-1.56
P/B Ratio		2.42
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		4.33
EV Multiple		-1.22

Metric
Days Sales Outstanding		124.77
Days Payables Outstanding
Days Inventory Outstanding		0.00
Operating Cycle		124.77
Cash Conversion Cycle		-111.15
Asset Turnover		0.38

Metric
Operating Cash Flow		-111.62M
Free Cash Flow		-115.93M
Cash Flow to Debt		-0.44
Operating Cash Flow/Sales		-0.44
Free Cash Flow Yield		-0.57

Metric
Cash & Equivalents		69.27M
Accounts Receivable		-28.96M
Inventory
Goodwill
Debt to Capitalization		0.62
Debt to Assets		0.09
Current Ratio		5.18
Quick Ratio		5.05

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.50
R&D to Revenue		3.49
SG&A to Revenue		1.24